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INTRO-
DUCTION
This is the report of proceedings from the Dublin 
Drug Policy Summit, which was held in Dublin 
on 20th January 2017. The summit was hosted 
and organised by the Ana Liffey Drug Project, 
and brought together national and international 
experts in drug policy to talk about two key 
issues in current Irish drug policy – supervised 
injecting facilities and the decriminalisation 
of possession of drugs for personal use. The 
summit was held under the Chatham House 
Rule, and this report is consistent with that 
rule – what is reported on are the themes of the 
discussions, but no individual or organisation 
is identified as having made any particular 
statement. The report was prepared from the 
substantial notes of two observers from the Irish 
Management Institute who were in attendance 
on the day, with feedback on a first draft being 
provided by the Ana Liffey Drug Project prior to 
completion. Points reported are not presented 
in strict chronological order, but are rather 
grouped as general themes.
‘AT THE SUMMIT, 
WE HAD THE 
BENEFIT OF 
THE EXPERTISE 
AND INSIGHT 
OF BOTH 
ACADEMICS AND 
PRACTITIONERS 
IN BOTH AREAS.’
Catherine Byrne, who attended in her capacity 
as Minister of State with responsibility for the 
National Drugs Strategy. 
Finally, I am pleased to say that since the 
completion of the summit I have been able 
to follow Minister Byrne’s work in introducing 
the Misuse of Drugs (Supervised Injecting 
Centres) Bill 2017 to the Oireachtas. I wish the 
Minister well for its passage and subsequent 
implementation. 
I have no doubt that the conversation on 
supervised injecting and decriminalisation in 
Ireland will continue among policy-makers, civil 
society and the communities they serve. I hope 
and trust that this short report will be of value in 
informing those conversations.
Eva Maguire   
Chairperson
March 2017
CHAIR-
PERSON’S 
FOREWORD
The Dublin Drug Policy Summit brought 
together leading figures from Europe, North 
America and Australia to discuss two topical 
issues in drug policy – supervised injecting 
facilities and decriminalisation. These are both 
concepts which potentially challenge the status 
quo, and as such they can raise fears for many 
people. They are, however, also topics which are 
not specific to an Irish context. Indeed, many 
countries have implemented, or are actively 
considering implementing, policy in these 
areas. At the summit, we had the benefit of the 
expertise and insight of international academics 
and practitioners in both areas.  The purpose 
of the session was to help Ireland, as a country 
learn from their experiences as we consider the 
practicalities of policy change. 
As Chair, I’d like to extend my thanks to a few 
groups and individuals. First, to all the delegates 
who attended and participated – there was 
great energy in the room and this always makes 
the role of Chair significantly easier, for which 
I am grateful. There was much discussion and 
insight shared on both topics, which I believe 
has been well captured in this short report.  
Second, to the Ana Liffey Drug Project, Open 
Society Foundations, the London School of 
Economics and the Irish Management Institute 
who respectively organised and supported the 
event. 
Third, I would also like to extend my personal 
thanks to the keynote speakers on the 
day. Madame Ruth Dreifuss attended and 
contributed in her capacity as Chair of the 
Global Commission on Drug Policy. It was 
wonderful to benefit from her experience as our 
guest of honour and I greatly enjoyed sharing 
the day with her. The same is true of Minister 
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STRUCTURE 
OF THE 
SUMMIT
The agenda for the day is provided at Appendix 
B. In essence, the event was broken into four 
main areas:
1 A brief introductory session which included:
a) A brief statement from the CEO of Ana 
Liffey, Mr. Tony Duffin
b) A tour de table
c) An Opening Address from Catherine 
Byrne TD, Minister for State for Commu-
nities and the National Drugs Strategy 
d) A Keynote Address from Madame Ruth 
Dreifuss, Chairperson of the Global 
Commission on Drug Policy and former 
President of Switzerland.
2 A module on key issues in supervised 
injecting in Ireland which included a 
presentation from the CEO of Ana Liffey, 
Mr. Tony Duffin followed by a roundtable 
discussion for all delegates facilitated by the 
summit Chairperson, Ms. Eva Maguire
3 A module on key issues in decriminalisation 
in Ireland which included a presentation 
from Ana Liffey’s Head of Policy, Mr. Marcus 
Keane followed by a roundtable discussion 
for all delegates facilitated by the summit 
Chairperson, Ms. Eva Maguire
4 A closing session
Ana Liffey has taken an active role in the public 
debate around these issues, and in providing 
civil society input into their development and 
progression as policy approaches.  Ana Liffey 
is explicitly supportive of both supervised 
injecting and of decriminalisation of possession 
for personal use, but recognises that not all 
countries are the same and that it is important 
that the correct path forward is identified for 
the Irish context.  The aim of the summit was to 
share learning from around the world on these 
important topics. Delegates included domestic 
and international experts from statutory and 
non-statutory agencies. A delegate list is 
provided at Appendix A.
CONTEXT
A group gathered in Dublin to discuss two 
significant developments in the Irish policy 
approach towards drugs and drug use, those 
being:
1 The Programme for a Partnership 
Government notes that the government “will 
support a health-led rather than criminal 
justice approach to drugs use including 
legislating for injection rooms” 1. Legislation 
which will create the legal framework 
within which supervised injecting facilities 
can lawfully operate is expected to be 
introduced to the Dáil in February 20172, 
and monies have been allocated in the 
national budget for expenditure on this 
project in 2017. The establishment of a 
pilot centre appears in the Health Service 
Executive’s workplan for 20173.
2 In November 2015, and in line with a 
health-led position on drug use, the Joint 
Committee on Justice, Defence and Equality 
“strongly recommend[ed] the introduction 
of a harm reducing and rehabilitative 
approach, whereby the possession of a 
small amount of illegal drugs for personal 
use, could be dealt with by way of a civil/
administrative response and rather than via 
the criminal justice route.”4  
1  See http://www.merrionstreet.ie/MerrionStreet/en/ImageLi-
brary/Programme_for_Partnership_Government.pdf , p56
2  The Bill was, in fact,  presented on 08/02/2017
3  https://www.hse.ie/eng/services/publications/serviceplans/
Service-Plan-2017/2017-National-Service-Plan.pdf 
4   See http://www.oireachtas.ie/parliament/media/committees/
justice/Final-Report---For-Publication.pdf 
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INTRO-
DUCTORY 
SESSION
WELCOME AND THANKS
The delegates were welcomed. It was noted 
that they were a diverse group, all with specific 
expertise in drug policy and / or healthcare 
service delivery.  Delegates included a person 
who has injected drugs, clinicians, researchers, 
academic experts, community workers, policy 
experts and representatives from relevant 
statutory bodies. 
2 Decriminalisation does not imply a lack of 
consequences.  However, it does permit a 
health based, person centred approach to 
be taken, and avoids the person having the 
stigma of being criminalised.
3 It is important to be clear in 
communicating precisely what is meant by 
‘decriminalisation’ as this often isn’t clear.
4 Threshold limits are likely to be a necessary 
part of any decriminalisation model. These 
must be carefully selected and the approach 
taken to enforcement must be flexible.
5 Whilst there was significant support for 
decriminalisation as a policy for Ireland at 
the summit, it was not unanimous, and not 
all delegates agreed that decriminalisation 
was the correct drug policy choice for 
Ireland.
1 People who inject drugs and other 
stakeholders should be consulted regarding 
service design and implementation. The 
service must be appealing to people who 
inject drugs in the public domain; it must be 
a discreet service that they trust; and it must 
be a sanctuary where they feel safe.
2 Access criteria to the facility should not be 
specifically legislated for. There is a need 
to maintain flexibility, such that people 
are not needlessly excluded. It may be the 
case that there are different operational 
protocols which apply to different groups, 
but as a general rule whether or not any 
individual can access the centre should be 
on the basis of an informed decision by the 
person seeking to access the centre and the 
responsible person running the centre at the 
time.
3 It is important to be clear on the benefits of 
Supervised Injection Facilities, and on their 
limitations. They will improve amenity by 
reducing consumption of drugs on the street 
and will lead to positive health outcomes 
for drug users. They will not solve the drug 
problem or decrease drug consumption.  
4 There are challenges in operating drug 
consumption rooms. As a new service, 
staffing, policing and engaging the 
community will all require focus, but are 
all issues which have been addressed 
successfully in other jurisdictions.
The decriminalisation of possession of small 
amounts of drugs for personal use is not current 
government policy, but it has been the focus 
of attention in recent times from legislative 
structures such as the Joint Oireachtas 
Committee. There is an ongoing conversation 
in Ireland about decriminalisation as a policy 
choice. As this conversation continues, the 
following are the broad considerations which 
emerged from the day.
1 Decriminalisation is consistent with a 
health led approach to dealing with drug 
use. However, a mere change in the law is 
unlikely to have a significant effect either 
way on levels of use.
EXECUTIVE 
SUMMARY
The establishment of a supervised injecting 
centre is government policy and policy makers 
are working towards an implementation date 
within the coming months. As they do so, the 
following are the broad considerations which 
emerged from the day. 
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ON SUPERVISED INJECTING FACILITIES
Such facilities should and could be much more 
than just monitoring injections. They provide an 
opportunity for relief from the dangers that face 
many drug users and also opportunities to have 
conversations with peers, and to access other 
medical and social services.
Such facilities should be adaptable to new 
problems, new drugs and new trends in drug 
use. 
In the Irish context, a drug checking service 
might also be considered – ensuring consumers 
know what is in what they have bought, how 
pure/impure and the strength of the substance. 
Such services are already in place in some 
countries at music festivals and night clubs 
where drug samples can be tested at fixed 
points and in mobile labs. This can help give up 
to date information on drug trends.
Ireland has already taken important and 
pragmatic steps in drug policy with its 
commitment to safer injecting spaces and 
openness to discussions on decriminalisation. 
In this regard, Ireland must be viewed in the 
context of a broader picture, that dealing 
with drug issues is a work in progress all 
over the world which, while not exactly the 
same everywhere, is nonetheless a different 
combination of the same core elements, 
including:
1 A public health emergency with social 
consequences
2 Prejudice against drug consumers -  
especially the poorest and most at risk, 
including ethnic minorities
3 Lack of access to services and housing for 
the most vulnerable drug consumers
4 A growing global black market, whether 
repression is strong or not
5 An increase in organised crime with a large 
influence on society 
6 Higher level of violent crime
7 A loss of credibility of states and their laws
In this context, the need for an animated 
public debate and genuine participative 
collaboration in policy implementation between 
all stakeholders is understood as compulsory. 
There was consensus in the room that not every 
model will work for Ireland, but by undertaking 
this type of collaborative approach and 
applying the best of what works elsewhere and 
contextualising it to Ireland’s specific needs, a 
well informed and culturally suited approach 
can be identified and adopted. 
advisors and field workers must work to ensure 
a high level of public awareness of the facts 
around safe injection facilities is available. 
A growing level of interest in relation to 
decriminalisation as a policy choice in Ireland 
was noted, with increasing attention paid to 
models in places like Portugal. A parliamentary 
visit to Portugal had highlighted the long term 
stigma that can affect prospects for employment 
and social cohesion caused by criminal 
convictions for the possession of relatively small 
amounts of drugs for personal use. 
‘AN OBLIGATION 
EXISTS TO 
MINIMISE HARM 
AND TREAT 
ADDICTION 
NO MATTER 
THE METHOD 
OF DRUG 
CONSUMPTION.’
It was noted that 2017 is an important year 
for the Ana Liffey, which celebrates 35 years 
in existence, having been established in 1982. 
Thanks were extended to the Irish state and 
to statutory bodies such as the Health Service 
Executive, which provide the vast majority of the 
funding for Ana Liffey’s services. Gratitude was 
expressed to partners of the Ana Liffey for their 
support for the event, and in particular to the 
London School of Economics, the Open Society 
Foundations and the Irish Management Institute
INTRODUCTION TO THE DAY
The scope and purpose of the day was 
discussed. It was noted that there were a wide 
range of factors that will require consideration 
from the various stakeholder groups in 
progressing the issues of supervised injecting 
and decriminalisation, and that learning from 
the day’s forum should be taken forward. It was 
recognised that not all stakeholders were in 
attendance on the day.
THE POLICY CONTEXT
It was noted that there will be a new National 
Drug Strategy in 2017, focused on reducing 
the harm caused by drug use and continuing 
to build on the foundations laid by previous 
policies and previous administrations. The 
process to create the new policy included 
submissions from a wide variety of stakeholders. 
The lessons from, and experience gathered in 
the forum can help inform the strategic choices 
around drug policy in Ireland. The importance 
of including the views of people who use drugs 
themselves was noted. 
The Government’s commitment to a health-led 
approach to drug use was underlined by its 
support for supervised injecting facilities. Street 
based injecting poses a significant health risk to 
users and to the community and a pilot project 
for safe injection facilities is planned in 2017. 
Learning outcomes from the pilot project should 
in turn be applied to inform wider, future policy 
development. The importance of designing the 
pilot with robust and appropriate data collection 
methodologies at the outset was stressed. It was 
also acknowledged that policy makers, expert 
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PEOPLE
ACCESS CRITERIA
There was a discussion about access and about 
who should be permitted to use the facility:
Access should be broad
There was a general agreement that access 
should be as broad as possible and that the 
introduced legislation should steer away from 
excluding certain groups from accessing the 
service (e.g. under 18s, pregnant women, etc.).
This was backed up by the experience in Sydney 
where a number of exclusionary criteria are in 
place (e.g. must be an already established user, 
no pregnant women, no under 18s, must not be 
significantly intoxicated).  It was argued that if 
someone is already an injecting drug user, they 
should be welcomed even if they don’t meet the 
other criteria above as it is in their best interest 
to access the services and support that they 
require as they need it.
It was, however, stated that access should 
be given only if the person presenting is an 
injecting drug user so as not to assist someone 
in becoming an injecting drug user.
There can be tailored protocols for  
certain groups
It was noted that specialised protocols can be 
put in place for particular groups and clinicians 
on the front line can make decisions on a 
case-by-case basis which are in the service 
users’ best interests.  In the case of younger 
injecting drug users, it is important that we 
become aware that they are using as early as 
possible so that interventions can be planned. 
There is nothing to be achieved by using the law 
to blanket block access to a particular group.
It would be better to have less specific direction 
in law such that it could be left to the clinician 
and the service user on the front line to make 
access decisions based on the specific situation 
at the time of access.  
MODULE 1: 
SUPER-
VISED 
INJECTION 
FACILITIES
The following summarises the key points 
discussed during the session on Module 1: 
Supervised Injecting Facilities, grouped under 
the broad headings of people, place and 
policing.
ON DECRIMINALISATION
It is important to be clear about what decrim-
inalisation means, and to what it applies. In 
general, the issue is in changing the criminal 
law to decriminalise possession for personal 
use (and, in some cases, petty, non-violent drug 
crime), reducing harm and allowing the police 
and legal system to focus their resources on 
drug dealers and organised crime.
Criminalisation itself is in large part responsible 
for problems like stigmatisation. In moving 
to a health-led approach it is hoped that in 
time people will accept that to support people 
who use drugs problematically, it can be 
recognised that proper care is required rather 
than criminalisation. Society at large needs a 
supportive architecture of compassion to enable 
perceptions to change. 
There are many ways to decriminalise, or at 
least reduce criminalisation that have been 
implemented in other countries. There is no 
“one-size-fits all”, prescriptive solution. As a 
nation, Ireland must attempt to find a lower 
level of repression, one that abandons the 
stance on removing the rights of people to 
choose which drugs are acceptable. Alcohol 
and cigarettes were raised as examples of 
dangerous, addictive substances with huge 
personal and social costs attached, yet society 
does not seek to control simple possession or use 
via the criminal law. 
It was noted that the markets for cigarettes 
and alcohol are legal and regulated. Though 
important to distinguish decriminalisation from 
regulation, it was noted that regulating markets 
can remove them from the criminal sphere. 
If done properly, regulation can help States 
minimise harm by moderating the production 
and sales environment in the same way that 
exists for chemicals, medicines and food.
There was a semantic difference highlighted  
between supervised consumption and 
supervised injecting and that the pragmatic 
consequences of focussing on one particular 
method of drug use at the exclusion of all others 
needed to be acknowledged. An obligation 
exists to minimise harm and treat addiction 
no matter the method of drug consumption. 
Further, if there are other means of use that are 
less harmful than injecting then facilities should 
encourage this. The semantic distinction was 
also noted between ‘safer’ and ‘supervised’ in 
the context of drug consumption spaces.
‘SOCIETY AT 
LARGE NEEDS 
A SUPPORTIVE 
ARCHITECTURE 
OF COMPASSION 
TO ENABLE 
PERCEPTIONS 
TO CHANGE.’
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Not overly clinical
Some facilities are located in medical and 
clinical buildings.  This could be off-putting for 
potential users as it may be too administrative 
and too medical and not appealing as a place 
to approach.  This was contrasted with facilities 
such as that in Copenhagen, where the set-up 
is not overly clinical in nature. A Supervised 
Injecting Facility should be a sanctuary for 
people, where trust increases and therapeutic 
relationships can develop.
Currently, drug use occurs in parks, public toilets 
and anywhere people can readily access but 
remain secluded.  Drug use is not permitted on 
private or business premises including drop-in 
centres and homeless hostels, but the reality is 
that it does happen in all these locations. Many 
services have clinical waste bins in the toilets. 
PLACE
THE BUILDING
There is a need to consider the best 
environment for this facility.  It should be clean 
- but should it be clinical or should it be more 
hospitable? A discussion was held on this and 
the following points were noted:
There is facility in the Sydney centre for two 
people to use drugs together in a booth if they 
present together at the centre.  In these cases, 
there may be some sharing of substances.  
However, drugs in Australia are expensive so 
the substances may have been jointly procured.  
Sharing and selling of drugs is not permitted 
outside of these circumstances.  There is a legal 
basis for injection, but not for sale or purchase. 
In Ireland, it was noted that the law would be 
applied differently and that it would not be 
possible for sharing to take place.
Staffing 
The staffing needs and implications of 
supervised injecting facilities were discussed. 
The following points were noted:
Attitude is key
There is a paradox in having healthcare staff 
supervise injecting, an inherently dangerous 
activity, particularly where the substance to be 
injected may be unknown. In the Sydney case, 
a medical approach to staffing the centre was 
taken and there is a part time Medical Director, 
a part time Operations Director and floor staff 
including Nurses and Health Education Officers.  
In practice, Health Education Officers can 
manage most situations but nurses are required 
to carry out certain interventions.  What is key is 
that staff members need to be able to deal very 
humanely with the service users.
Consider practicalities
Medical involvement helps identify the facility 
as a health service and it also reinforced the 
strategy of approaching this with a health lens 
rather than a criminal justice one.  However, 
it was noted that there can be a considerable 
burden on a Clinical Lead who is regularly on 
call and that this should be considered early in 
the planning for the facility.
It was noted that although staff will not 
always know what substances may have been 
consumed before someone presents at the 
facility, this can be assessed in real time and 
if there is an adverse reaction, the person is 
in a place where they can receive appropriate 
treatment.  Overdoses can be assessed 
according to clinical criteria and can be 
managed proactively through monitoring and 
intervention when appropriate.
AN APPEALING SERVICE FOR 
POTENTIAL SERVICE USERS
The Supervised Injecting Facility needs to be a 
facility that is appealing to service users.  It is 
therefore important that potential service users 
are consulted to understand what kind of facility 
they would use, and it was stated that there is 
some work underway to this end. The following 
was noted in this regard:
There is both curiosity and apprehension
Apprehension about such services does exist 
and there was a concern that there may be 
reluctance amongst some potential service 
users to attend the Supervised Injection Facility.  
However, there is also a curiosity amongst 
the target user group and they are anxious to 
understand what it will be like and how it will 
work.
A smiling welcome is important
From the experience of existing services, it 
was noted that although the locale, facilities 
and aesthetics of the service are all important 
what really makes the facility appealing is the 
atmosphere and the approach of staff.  The 
smile and welcome you receive when walking 
through the door is key, and this will spread by 
word-of-mouth. A person centred approach, 
focused on building relationships is useful in this 
regard.
The service needs to be accessible
It was noted that people engaged in injecting 
in the public domain do not typically travel 
before they use, but tend to use close to where 
they purchase their drugs. It was suggested that 
‘NIMBYISM’ may be an issue and people may 
be concerned about a honeypot effect, although 
it was noted that the evidence did not show that 
supervised injecting facilities had any sort of 
honeypot effect. 
The service should seek to include, not exclude 
people. The service should be very flexible in 
terms of sanctions, only denying access in 
very narrow circumstances such as significant 
violent incidents.
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No increase in crime
International examples show us that there 
is no increase in crime associated with the 
introduction of Supervised Injecting Facilities.  
There has been some evidence of a reduction 
in certain types of crime and this should be 
explored further.  Nonetheless, it was noted that 
supervised injecting is not a criminal justice 
intervention and should not be expected to 
impact significantly on crime, either positively or 
negatively.  The key benefits will be in terms of 
service user health and public amenity.
No market influence
Similarly, it was noted that supervised injection 
facilities do not affect the drug market with sale, 
purchase and use continuing in the same areas.  
The presence of a Supervised Injecting Facility 
doesn’t influence the market, and is instead 
a response to an existing problem. However, 
Supervised Injecting Facilities can give real 
time drug trend updates and can respond more 
rapidly to emerging needs which has benefits.
ROLE OF POLICING
With the intense focus expected on the 
Supervised Injecting Facility in the early days 
many questions arose around the policing of 
the centre. The following points were noted on 
policing and supervised injecting:
The importance of law enforcement
The role of law enforcement agencies cannot 
be underestimated and the success of the 
project will depend on all stakeholders working 
together.  In general, a relationship of trust 
between police and management of the facility 
is very important and a transparent relationship 
must be built from day one.  Police must not 
target the centre and users but also must 
not avoid it.  All police in the area should be 
educated on how to police the centre.  This could 
form part of induction for all new police as well 
as a tour of the centre to see it first hand and 
dispel any myths.
Different solutions for different jurisdictions
Different jurisdictions operate different 
approaches in relation to policing. In 
Switzerland, police do not generally enter 
the centre unless they have been called for 
assistance in a violent case.   
the area. In this regard, there is a need for good 
baseline data on key indicators such that the 
effectiveness of the facility can be measured 
and in order to capture any changes in opinion 
in society around the introduction of the 
Supervised Injecting Facility.
INTEGRATION WITH OTHER SERVICES
Supervised Injecting Facilities need to be 
embedded within the service landscape and it 
was noted that there was a need to integrate 
the Supervised Injecting Facility with existing 
services, including higher threshold treatment 
options.  A discussion was held on this, with the 
following noted:
The need for pathways
With most Supervised Injecting Facilities, there 
is a three stage approach; reception, injecting 
room and an area to relax and interact.  In the 
third stage, access to other related services can 
also be offered. The importance of identifying 
and defining pathways for people through the 
service and to other services was emphasised. 
Provide what people want and need 
In general, other services can also be provided 
to people at the facility such as basic food, 
showers, or laundry services.  Having access to 
such services is important and can help change 
the perception people have of themselves.  In 
considering what services to include, the needs 
of potential service users must be taken into 
account.
POLICING
IMPACT ON DRUG MARKETS  
AND CRIME LEVELS 
Members of the public may be concerned about 
the impact Supervised Injecting Facilities have 
on crime levels and drug markets. These matters 
were discussed and the following was noted: 
In the city centre
In the context of Dublin, it was noted that a city 
centre location made sense. It was also noted 
that Dublin was not the only location where 
stakeholders had called for implementation 
of supervised injecting facilities. In particular, 
stakeholders in Cork have identified a need for a 
Supervised Injecting Facility and have identified 
a suitable building.
Potentially mobile
A Supervised Injecting Facility is a local solution 
to a local problem.  However, one possible 
variable is to have mobile facilities which can 
follow the flow of the population.  This would 
allow authorities to move the facility if the 
location of drug use changed and they could 
also service events where drug use is common 
such as festivals. However, mobile units have 
limitations with regards to capacity due to their 
size.
ENGAGING THE COMMUNITY
There is great interest in the community about 
where the facility will be located.  There are 
a lot of stakeholders and ‘NIMBYISM’ will 
undoubtedly be an issue.  This issue was 
discussed and the following noted:
The need to engage proactively
Existing services in Dublin spend a significant 
amount of time engaging with the local 
community and issues around anti-social 
behaviour and congregation are often cited 
as objections to services.   In other locations 
input regarding supervised injecting centres 
is garnered from the community at regular 
meetings.  This on-going consultation 
has emerged as an important element of 
the ongoing management of Supervised 
Injecting Facilities.  Fears can be allayed by 
street visibility. In other locations, there are 
security staff on duty to manage and prevent 
congregation and congestion inside and outside 
the building. 
The need for good data
Communities had, after initial opposition, 
generally been welcoming to Supervised 
Injecting Facilities where they had been 
introduced as they had had a positive effect on 
‘A SUPERVISED 
INJECTING 
FACILITY 
SHOULD BE A 
SANCTUARY 
FOR PEOPLE, 
WHERE TRUST 
INCREASES AND 
THERAPEUTIC 
RELATIONSHIPS 
CAN DEVELOP.’
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  ‘THE POSSIBILITY OF 
CRIMINAL SANCTION IS 
NOT A DETERRENT TO 
DRUG POSSESSION AND 
USE FOR SOMEONE WHO IS 
DEPENDENT – NECESSITY 
KNOWS NO LAW AND WHAT  
MUST BE DONE, MUST BE 
DONE.’
In Sydney, there is no ‘free zone’ around the 
centre. There is support from local police, and 
people coming to use the service are not actively 
targeted on the sole basis of a belief that they 
are heading towards the Supervised Injecting 
Facility and could be in possession of drugs.  
Where people are stopped, police in Sydney 
often use their discretion not to charge for 
possession, but they do still confiscate. 
It was noted that people working in addiction 
services can feel like they are working in a ‘gray 
area’, given that they are working with people 
who by the nature of their addiction will often 
be in possession of drugs, thereby creating a 
potential criminal liability for staff and clients 
unless addressed appropriately. It was also 
noted that the possibility of criminal sanction is 
not a deterrent to drug possession and use for 
someone who is dependent – necessity knows 
no law and what must be done, must be done.
In the Irish context, it was noted that police are 
very aware of the complexities of policing in the 
context of social and health issues and take a 
very pragmatic approach to dealing with people 
on the street every day.
The importance of discretion
Discretion is important in policing supervised 
injecting facilities, and it was acknowledged that 
this presents challenges. Discretion is something 
which needs be applied consistently, and 
legislative clarity assists with this. If things are 
unclear, a very nuanced approach to complex 
issues is required, and it can be difficult to get 
a consistent approach. It is important that the 
facility is properly policed but not targeted. It 
was noted that policing is about all aspects of 
community safety and support, including health, 
and that police forces understand the role of 
consumption facilities in communities where they 
are needed. In terms of people using the centre, 
common sense dictates that if someone is merely 
walking towards the centre, there is no need to 
intervene absent any other reason. It was noted 
that issues of public injecting in Dublin city centre 
are currently policed in a conscientious way, and 
there is a lot of good collaborative work on the 
ground between the Gardai and other statutory 
services and NGOs.  
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RESPONSES 
A discussion about responses also took place, 
with the following points noted:
A need for appropriate responses
Decriminalisation does not mean an absence 
of consequences, and that needs to be clear.  It 
doesn’t mean that the activity is not prohibited 
or frowned upon.  It just isn’t dealt with through 
the criminal justice system.
The Joint Oireachtas Committee report 
recommended dealing with possession with 
a civil administration response.  Research 
must be done to ensure the appropriate 
response in the Irish context.  Factors 
identified by the Committee such as role and 
discretion of statutory services; application 
on a case-by-case basis; and investment in 
education and training must be addressed.
Should support a health based response
Different jurisdictions have used different 
responses. It’s important not to adopt any 
approach that could be more punitive in 
practice than criminalisation, or one that 
can lead to criminalisation by other means. 
Fundamentally, decriminalisation is about 
supporting a health led rather than a criminal 
justice led approach to drug use. It is not about 
adopting alternative, but equally punitive 
approaches to the issue. 
In this regard, it was noted that some international 
commentators have argued against punitive 
penalties for certain drug related offences.  
Interventions should be health based, tailored to 
the individual and voluntary.  The assumption 
that if you punish someone, they won’t do it again 
doesn’t work for drug users.  There is no reason to 
punish someone for something which may bring 
harm to themselves, but not to others. Further, 
the law courts are not the appropriate setting for 
engaging with a health issue like drug use.
An alternative perspective was that possession 
offences could involve a civil sanction rather 
than a criminal sanction but that the response 
should send a message that it is not acceptable 
for people in our society to take the risks 
associated with drug use.
Under a criminalisation policy, the basic idea 
is that if a state punishes people who do things 
which are at odds with what society considers 
acceptable, then people will be deterred 
from doing those things.  However, punishing 
possession for personal use has not been 
shown to have any significant deterrent effect. 
In reality, the crime of simple possession is not 
respected by large amounts of people, which 
undermines its credibility and the rule of law. 
Nor does a policy of criminalisation affect 
all groups in society equally - people from 
disadvantaged areas are more likely to be 
criminalised than other members of society. 
Similarly, a policy of criminalisation has a 
negative effect across other policies - if a state’s 
policy is societal reintegration of people who 
use drugs, criminalisation goes in the other 
direction.  Labelling someone as a criminal can 
have lasting negative consequences. 
The importance of language
It was noted that language can be important. 
Many people are instinctively against 
decriminalisation, but agree with a health based 
approach to drug use. Decriminalisation needs 
to be framed as a health and social issue rather 
than a criminal one.
Some concerns remain
There were concerns that a decriminalisation 
policy could lead to an increase in drugs 
coming into Ireland and that this additional 
supply element could have consequences for 
law enforcement. There were also concerns 
that a decriminalisation policy could send 
the wrong message to people, particularly 
under 18s.   However, it was also noted that the 
criminal justice system is not the best way to 
communicate health promotion messages to 
people - young or old.
Balance is important
It was noted that dealing with drugs in society 
is a complex matter and that balance was 
important in drug policy generally. Going too 
far either way on a restrictive / permissive 
spectrum is likely to result in significant 
harms and be unhelpful as a policy approach 
attempting to minimise harm, and there is a 
need to ensure that this is understood. 
GENERAL DISCUSSION 
There was a discussion about decriminalisation 
generally as a policy approach. The following 
were the key points noted:
Decriminalisation is not a panacea
It is important to not overstate the benefits or 
impacts of decriminalisation. The reality is that 
(de)criminalisation has little or no impact on 
levels of drug use in an open society.  Drug use 
is a complex issue, and a binary choice between 
criminalisation and decriminalisation is unlikely 
to have a great effect either way.
It is true to say that there have been better 
outcomes for drug users in, e.g., Portugal 
since decriminalisation, but these benefits 
cannot simply be ascribed to the change in 
the law. Rather, they are more likely to reflect 
a broader policy shift which included the 
legal change, but also investment in services 
and the establishment and operation of the 
commissions of dissuasion.
Criminalisation is harmful
Nonetheless, criminalisation causes 
unnecessary harms. Prohibitionist policies 
don’t demonstrably impede drug markets, but 
they do have other effects. For example, they 
affect the way professionals engage with drug 
users. If a service provider becomes aware that 
a person is in possession of drugs, they must 
take steps to address this to ensure they are not 
exposing staff to criminal liability. Under current 
laws, users are by definition criminals and 
criminalisation is stigmatising. It can contribute 
to drug users remaining cautious about 
accessing services. Thus, there is a fundamental 
contradiction in the current system, where 
drug use is recognised as a health issue, but 
in order to receive assistance for that issue it 
is necessary for the person to be labelled as a 
criminal. 
MODULE 2: 
DECRIMI-
NALISATION
The following summarises the key points 
discussed during the session on Module 2: 
Decriminalisation, grouped under the broad 
headings of general discussion, responses and 
threshold limits.
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Focus on the needs of the individual
In Portugal, the initial goal was not to have a 
threshold chart, but this led to ambiguity and 
a chart was introduced. However, the system 
retains flexibility – it is always open to the court 
to refer a matter to the health authorities, or 
vice versa. This helps to ensure that there is 
not too much weight placed on the threshold 
amounts – the focus should be on the needs of 
the individual where personal use is the issue. 
  
Thresholds are needed
It seems inevitable that some thresholds will 
need to be defined.  With no threshold, the 
quantity of drugs considered within or beyond 
a personal use limit is open to inconsistent 
interpretation. 
Thresholds should not be rigid
Threshold limits must be carefully selected 
and the approach taken must be flexible. It 
is important that the thresholds are realistic. 
Otherwise, there is the risk of the decriminalised 
system being harsher than that under the 
criminal law.
It was noted that policing in Ireland is often 
focused on supply issues and that there is a 
significant level of compassion and practicality 
in the way drug use is addressed.
THRESHOLD LIMITS
Threshold limits – the amount of drugs one can 
possess before the focus shifts from personal 
use to possession for sale or supply – were also 
discussed. The following summarises the main 
points:
Lessons from elsewhere
In terms of other jurisdictions, it was noted that 
in Portugal possession for personal use was 
decriminalised and responsibility was moved 
from the criminal justice system and placed under 
the Ministry for Health.  The health administration 
authority has the power to apply sanctions.  In 
practice, the substance is not the issue but the 
pattern of use of the individual.  Each person 
needs to be dealt with on a case by case basis.
The current system in Portugal works better 
than what was there before.  It is much more 
focused on the person, and because the function 
is under the Ministry of Health, people are more 
willing to take the guidance being offered.  It is 
not perceived in the same way as a court of law, 
which is important. It also allows police to focus 
on and deal with supply rather than possession.
The focus in Portugal now is clearly on health 
issues and health problems.  This can be 
contrasted with the previous situation. Under 
criminalisation, if a drug user comes for help, he is 
admitting that he’s a serial criminal. Without this 
stigma, all other interventions are made easier 
and more accessible to those who need them.
In Portugal, decriminalisation was intended to 
make things be more fluid.  It’s important to note 
that when possession was considered a crime, 
the courts were generally applying the same 
sanctions which are now applied by the Ministry 
for Health.  However, now the sanctions come 
without the criminal record, the stigma and the 
expending of large amounts of resources.
Drug courts are not decriminalisation
It was noted that drug courts are not an 
example of decriminalisation and the US courts 
were described as a cautionary tale in this 
regard. As the court is not a health setting the 
health of the person is not to the forefront. Also 
that there is a need to consider the incentive 
structures of law enforcement in relation to 
drug arrests in any decriminalisation policy. It 
was suggested that drug policing is used as a 
proxy in other countries for managing certain 
communities, although that this is not the case 
in Ireland. 
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Many thanks to Leonie Blyth, Lauren Crook,  
Paul Duff, Jacqueline Kenny and Dawn Russell - 
members of the Ana Liffey who worked tirelessly 
to ensure the Dublin Drug Policy Summit was 
successful.
 
CLOSING 
REMARKS
A brief closing session provided an opportunity 
to reflect on the day’s proceedings. The following 
key points were noted:
Implementation of a Supervised  
Injecting Facility
On the issue of creating a supervised injection 
facility, Ireland is close to seeing the Irish 
parliament pass legislation and then the 
real challenges of implementation will begin. 
In getting to this point, the work of previous 
governments was acknowledged, as were the 
many public and private advocates who have 
kept the issue in the spotlight.
Take the dialogue on decriminalisation 
forward
On the decriminalisation discussion, the 
discussion at the summit was a starting point, 
and it is now for individual politicians to find 
the best window to suit the political agenda 
and take this dialogue forward. It is true though, 
that it has been considered by legislators and 
perhaps that time is now. 
Honour the evidence
In general, our choices around drug policy 
should reflect good practise approaches and 
there should be a focus on the ways to get 
further, validated, reliable evidence into the 
debate. Academic research will play a part in 
this, as should existing and historical records – 
real human experience and individual cases.
Focus on reducing harm
A catalogue of harm reduction measures are 
needed to be effective in addressing the harms 
caused by existing and new substances and 
changing circumstances. This is a global issue, 
not only a local issue. Speaking in one voice is 
important, but so is being modest and bold at 
the same time. It will not all be done tomorrow, 
but Ireland is on the right path.
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APPENDIX B:
DUBLIN DRUG POLICY SUMMIT  
AGENDA 
FRIDAY 20th January 2017
09.00
09.20
10.00
10.10
10.40
Coffee / Tea 
Welcome - Chairperson 
• Format of the day
• Tour de Table
• Introduction of Minister Byrne
Opening address – Minister Byrne 
Keynote address – Madame Dreifuss 
Refreshment Break
11.00
11.10
11.45
13.00
Module 1 – Supervised Injecting
• Intro to structure of module - Chairperson
Key themes in supervised injecting in Ireland – Tony Duffin,  
Ana Liffey Drug Project. 
Chaired roundtable discussion on SIFs, focusing on key issues. 
LUNCH
14.00
14.10
14.45
16.00
Module 2 – Decriminalisation
• Intro to structure of module - Chairperson
Key themes in decriminalisation in Ireland – Marcus Keane,  
Ana Liffey Drug Project.
Chaired roundtable discussion on decriminalisation,  
focusing on key issues.
Refreshment Brea
16.20
16.50
17.00
17.00
18.00
Closing Session
• Review of day - Chairperson
Closing remarks by Madame Dreifuss
Close of Plenary Session
Side Meetings / Media
Close
Our vision is for a society where 
all people affected by problem 
substance use are treated with 
dignity and respect and have 
access to quality services. 
Our mission is to work with people 
affected by problem substance 
use and the organisations that 
assist them.  We do this to reduce 
harm to individuals and society, 
and to provide opportunities for 
development of those individuals 
and organisations.
ANA LIFFEY DRUG PROJECT, 
48 Middle Abbey Street
Dublin 1
www.aldp.ie
ana liffey drug project
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